Health and Medical News

Urigen Announces Early Closure Of URG101 Phase II Clinical Trial Based On Positive Interim Analysis

Health and Medical News - Urology & Nephrology
Wednesday, 09 April 2008
Urigen Pharmaceuticals, Inc. (OTCBB:URGP), http://www.urigen.com, announced the early closure of the URG101-104 study thanks to positive, statistically meaningful interim study results in both the primary and all secondary endpoints. The top line results of the interim study which was planned at 50% enrollment were previously released March 12, 2008. "Based upon further review, it has been determined continuing enrollment will not meaningfully alter the study conclusions. This decision allows us to now accelerate the full development of URG101," commented Urigen's Chief Scientific Officer, Dennis Giesing, PhD. The URG101-104 study was a pharmacodynamic and safety study investigating the treatment of painful bladder syndrome/ interstitial cystitis (PBS/IC). The cross-over design utilized provided sufficient power to reliably assess treatment effects using modestly sized study cohorts. This study in combination with preceding studies has treated a total of 200 subjects to date and further demonstrates URG101 is safe and well-tolerated. A final study of the study will be provided later in the quarter. "These positive clinical trial results imitate and enlarge my before work on URG101. Furthermore, it is exciting to me that these are among the best results that have been obtained in a multi-center trial for PBS/IC. It is meaningful to bear in mind that intravesical therapy is used throughout the country to treat PBS/IC and Urigen is working to standardize this therapy." commented C. Lowell Parsons, M.D., Urigen's Scientific Founder. About Urigen Pharmaceuticals, Inc. Urigen Pharmaceuticals is a specialty pharmaceutical company devoted to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs goal meaningful unmet medical requires and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. URG301 targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further info, please visit Urigen's website at http://www.urigen.com. Forward-Looking Statement This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology like "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no task to update any of the forward-looking statements, whether as a result of new info, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings. http://www.urigen.com

[ Back ]

Latest news in this category:

Overall Decrease In Kidney Cancer Deaths In Europe
Saturday, 12 April 2008
Overall deaths from kidney cancer have now fallen across Europe after peaking in the early 1990s, according to a detailed study of mortality rates for 32 countries published in the urology journal BJU International.

Acute Kidney Injury With Sepsis -- A Unique Pathophysiology
Saturday, 12 April 2008
ICU patients with septic acute kidney injury (AKI) are typically sicker, have a higher burden of sickness, a greater risk of mortality and longer stays in hospital than patients with non-septic AKI.

Major Surgery No Longer Needed For The Removal Of Uterine Fibroids
Saturday, 12 April 2008
The treatment of uterine fibroids with 3T MR-guided focused ultrasound (MRgFUS) is safe, non-invasive and effective, according to a recent study conducted by researchers at Weill Cornell Medical College in New York, NY.

InventHelp Client Invents Catheter Accessory For Patients Using Foley Catheter Urinary Drainage Bags
Friday, 11 April 2008
InventHelp announces that 2 of its clients, inventors from Drexel, N.C., have designed a health care accessory for individuals using Foley catheter urinary drainage bags. The inventors have built a prototype.

Drug Found Safe And Effective In Patients With Chronic Kidney Disease
Thursday, 10 April 2008
The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease (CKD), according to a study appearing in the July 2008 issue of the Journal of the American Society Nephrology.

University Of Queensland Kidney Researcher Attracts International Medal, Australia
Thursday, 10 April 2008
University of Queensland researcher Professor Wendy Hoy has been recognised internationally for her work on kidney disease. Professor Hoy has been awarded the United States National Kidney Foundation (NKF) International Distinguished Medal for 2008 at a ceremony in Dallas, Texas.

Overall Death Due To Kidney Cancer Fall In Europe - But Wide Variations Between Countries Still Exis
Wednesday, 09 April 2008
After peaking in the early 1990s, overall kidney cancer deaths have now dropped across Europe, according to a detailed study of mortality rates for 32 countries. The study is published in the journal BJU International (British Journal of Urology International).

Main Menu

Most popular articles

Latest News